SGLT2 Toys: A Cost-Effective Analysis

According In 2012, 29.1 million people in the United States, approximately 9.3% of the population were diagnosed with diabetes mellitus, of whom 90% to 95% of adults had type 2 diabetes[1]. Although drug costs are increasing, the greatest component of the economic burden of T2DM is the treatment of diabetic complications, which can be reduced with effective management of the disease[2]. The SGLT2 inhibitors are a novel anti-diabetic agents with similar glycemic efficacy to other oral anti-hyperglycemic agents and low risk for hypoglycemia. There is a lack of published literature evaluating the economic benefits of SGLT2 inhibitors such as dapagliflozin. This cost-effectiveness analysis evaluates the long-term economic consequences of SGLT2